Innovative control arms slash trial costs
The guest argued that the adoption of innovative control arms in clinical trials allows drug developers to bypass expensive placebo groups by utilizing historical control data.
The argument
Using Eli Lilly's trials as an example, the guest explained that matching historical control data with active cohorts eliminates the administrative overhead and cost of manufacturing placebos and monitoring those subjects. This methodology is seeing rapid adoption in China while remaining underutilized in the US.
The thesis, stress-tested
✓ What validates it
- ✓FDA issues formal guidance warming to synthetic or historical control arms
- ✓Eli Lilly or other major pharma report significant R&D cost reductions from historical control usage
▸ Risks discussed
- ▸Regulators like the FDA may reject trials lacking concurrent placebo controls
- ▸Data compatibility issues between historical and active cohorts
Hear it yourself
"There might be some more filling in of the data sources as time goes on. Sure. But, basically, you can just see where America stands in terms of running clinical trials. A lot most of our clinical trial pipeline is in phase twos. That's often where things fail. In phase one, they often fail too. I mean, every step, there are a lot of failures partly because of the rate? Like, if you take if you take of all the interventions that go into trials, it's, like, something like ten percent make it through Yeah. It's it's more than ninety percent failures."
AFFILIATE LINK · ZORTIX MAY EARN A COMMISSION · NEVER A RECOMMENDATION TO TRADE